CONTACT: Amber Wickard 570-214-4860
Oct. 17, 2012
FOR IMMEDIATE RELEASE
DANVILLE, PA - Two Geisinger staffers, Jonathan A. Bock, a research analyst in the Weis Center for Research, and Kimberly Fairley, DO, a fellow in gastroenterology, took first place honors for their poster at the 2012 Annual Scientific Meeting of the Pennsylvania Society of Gastroenterology, Sept. 28-30 in Skytop, PA.
Their poster, “An Economic Outcome Analysis of Incorporating Genome Sequencing with Triple Therapy in Treatment-Naïve Patients with Hepatitis C Virus Genotype 2/3 Infection,” was co-authored by Marc Williams, MD, director of the Genomic Medicine Institute, and Robert E. Smith, MD, Department of Gastroenterolgy/Hepatology.
This study used a treatment algorithm that includes triple therapy to examine the short and long-term cost-effectiveness of using IL28B genotype-guided therapy in treatment-naïve chronic HCV genotypes 2/3 patients. IL28B genotype-guided therapy was found to produce better outcomes but higher costs than standard of care (SOC) therapy in the short term. However, results from Markov modeling strongly suggest that in the long-term, therapy following our treatment algorithm leads to lower costs and a higher quality-adjusted life expectancy than SOC therapy, suggesting that therapy following our treatment algorithm could serve as a dominant cost-effective strategy for treating HCV genotypes 2/3.
Dr. Fairly and Mr. Bock presented their poster, along with 14 others, at the Pennsylvania Society of Gastroenterology’s Annual Scientific Meeting. The poster was very well received by physicians, vendors, and researchers alike, and ultimately won first place for the poster contest. Feedback from this meeting further strengthened their view that this is an extremely relevant and important study, and they hope to publish their findings in the coming weeks.
From left, are Jonathan Bock; Louis LaLuna, MD, President, PA Society of Gastroenterology;
and Kimberly Fairley, DO.
# # # #